Phenotypes associated with this allele

• Allele Symbol: Zbtb7b^m1Pgrs
• Allele Name: mutation 1, Philippe Gros
• Allele ID: MGI:8407069
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Zbtb7b^m1Pgrs/Zbtb7b^m1Pgrs	C57BL/6J-Zbtb7b^m1Pgrs	MGI:8407086

Genotype
MGI:8407086

hm1

• Allelic Composition: Zbtb7b^m1Pgrs/Zbtb7b^m1Pgrs
• Genetic Background: C57BL/6J-Zbtb7b^m1Pgrs

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

growth/size/body

enlarged spleen ( J:284753 )

• increased spleen CFU count after injection with M. bovis BCG

hematopoietic system

enlarged spleen ( J:284753 )

• increased spleen CFU count after injection with M. bovis BCG

increased CD8-positive, alpha-beta T cell number ( J:284753 )

• more single-positive T cells in spleen and thymus thymus during steady state and after injection with P.-berghei-ANKA-infected red blood cells

decreased alpha-beta T cell number ( J:284753 )

• fewer single-positive CD4+ in spleen and thymus and double-positive CD4+ CD8+T cells in thymus during steady state and after injection with P.-berghei-ANKA-infected red blood cells

decreased CD4-positive, alpha-beta T cell number ( J:284753 )

• fewer single-positive T cells in spleen and thymus during steady state and after injection with P.-berghei-ANKA-infected red blood cells

immune system

enlarged spleen ( J:284753 )

• increased spleen CFU count after injection with M. bovis BCG

increased CD8-positive, alpha-beta T cell number ( J:284753 )

• more single-positive T cells in spleen and thymus thymus during steady state and after injection with P.-berghei-ANKA-infected red blood cells

decreased alpha-beta T cell number ( J:284753 )

• fewer single-positive CD4+ in spleen and thymus and double-positive CD4+ CD8+T cells in thymus during steady state and after injection with P.-berghei-ANKA-infected red blood cells

decreased CD4-positive, alpha-beta T cell number ( J:284753 )

• fewer single-positive T cells in spleen and thymus during steady state and after injection with P.-berghei-ANKA-infected red blood cells

decreased acute inflammation ( J:284753 )

• resistance to experimental cerebral malaria (ECM) (reduced neuroinflammation, increased survival) after injection with P.-berghei-ANKA-infected red blood cells

• reduced leukocyte infiltration through blood brain barrier after injection with P.-berghei-ANKA-infected red blood cells

alveolitis ( J:284753 )

• increased alveolar disruption and necrosis in lungs after infection with M. tuberculosis H37Rv

increased susceptibility to bacterial infection induced morbidity/mortality ( J:284753 )

• increased spleen CFU count after injection with M. bovis BCG

• increased mortality and bacterial burden and myeloid and lymphoid cell infiltration in lungs after infection with M. tuberculosis H37Rv

• alveolar disruption and necrosis in lungs after infection with M. tuberculosis H37Rv

decreased susceptibility to parasitic infection ( J:284753 )

• higher survival rate after injection with P.-berghei-ANKA-infected red blood cells

mortality/aging

increased susceptibility to bacterial infection induced morbidity/mortality ( J:284753 )

• increased spleen CFU count after injection with M. bovis BCG

• increased mortality and bacterial burden and myeloid and lymphoid cell infiltration in lungs after infection with M. tuberculosis H37Rv

• alveolar disruption and necrosis in lungs after infection with M. tuberculosis H37Rv

respiratory system

alveolitis ( J:284753 )

• increased alveolar disruption and necrosis in lungs after infection with M. tuberculosis H37Rv